Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX™/Doxil®) versus conventional doxorubicin for first-line treatment of metastatic breast cancer

Mary E R O'Brien; N. Wigler; M. Inbar; R. Rosso; E. Grischke; A. Santoro; R. Catane; D. G. Kieback; P. Tomczak; S. P. Ackland; F. Orlandi; L. Mellars; L. Alland; C. Tendler

doi:10.1093/annonc/mdh097

Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX™/Doxil®) versus conventional doxorubicin for first-line treatment of metastatic breast cancer

Mary E R O'Brien, N. Wigler, M. Inbar, R. Rosso, E. Grischke, A. Santoro, R. Catane, D. G. Kieback, P. Tomczak, S. P. Ackland, F. Orlandi, L. Mellars, L. Alland, C. Tendler

Istituto Clinico Humanitas

Research output: Contribution to journal › Article › peer-review

Abstract

Background: This study was designed to demonstrate that efficacy [progression-free survival (PFS)] of CAELYX™ [pegylated liposomal doxorubicin HCl (PLD)] is non-inferior to doxorubicin with significantly less cardiotoxicity in first-line treatment of women with metastatic breast cancer (MBC). Patients and methods: Women (n = 509) with MBC and normal cardiac function were randomized to receive either PLD 50 mg/m² (every 4 weeks) or doxorubicin 60 mg/m² (every 3 weeks). Cardiac event rates were based on reductions in left ventricular ejection fraction as a function of cumulative anthracycline dose. Results: PLD and doxorubicin were comparable with respect to PFS [6.9 versus 7.8 months, respectively; hazard ratio (HR) = 1.00; 95% confidence interval (CI) 0.82-1.22]. Subgroup results were consistent. Overall risk of cardiotoxicity was significantly higher with doxorubicin than PLD (HR = 3.16; 95%CI 1.58-6.31; P

Original language	English
Pages (from-to)	440-449
Number of pages	10
Journal	Annals of Oncology
Volume	15
Issue number	3
DOIs	https://doi.org/10.1093/annonc/mdh097
Publication status	Published - Mar 2004

Keywords

Cardiotoxicity
Pegylated liposomal doxorubicin

ASJC Scopus subject areas

Oncology
Cancer Research

Access to Document

10.1093/annonc/mdh097

Fingerprint Dive into the research topics of 'Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX™/Doxil®) versus conventional doxorubicin for first-line treatment of metastatic breast cancer'. Together they form a unique fingerprint.

Cite this

O'Brien, M. E. R., Wigler, N., Inbar, M., Rosso, R., Grischke, E., Santoro, A., Catane, R., Kieback, D. G., Tomczak, P., Ackland, S. P., Orlandi, F., Mellars, L., Alland, L., & Tendler, C. (2004). Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX™/Doxil®) versus conventional doxorubicin for first-line treatment of metastatic breast cancer. Annals of Oncology, 15(3), 440-449. https://doi.org/10.1093/annonc/mdh097

Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX™/Doxil®) versus conventional doxorubicin for first-line treatment of metastatic breast cancer. / O'Brien, Mary E R; Wigler, N.; Inbar, M.; Rosso, R.; Grischke, E.; Santoro, A.; Catane, R.; Kieback, D. G.; Tomczak, P.; Ackland, S. P.; Orlandi, F.; Mellars, L.; Alland, L.; Tendler, C.

In: Annals of Oncology, Vol. 15, No. 3, 03.2004, p. 440-449.

Research output: Contribution to journal › Article › peer-review

O'Brien, MER, Wigler, N, Inbar, M, Rosso, R, Grischke, E, Santoro, A, Catane, R, Kieback, DG, Tomczak, P, Ackland, SP, Orlandi, F, Mellars, L, Alland, L & Tendler, C 2004, 'Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX™/Doxil®) versus conventional doxorubicin for first-line treatment of metastatic breast cancer', Annals of Oncology, vol. 15, no. 3, pp. 440-449. https://doi.org/10.1093/annonc/mdh097

O'Brien, Mary E R ; Wigler, N. ; Inbar, M. ; Rosso, R. ; Grischke, E. ; Santoro, A. ; Catane, R. ; Kieback, D. G. ; Tomczak, P. ; Ackland, S. P. ; Orlandi, F. ; Mellars, L. ; Alland, L. ; Tendler, C. / Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX™/Doxil®) versus conventional doxorubicin for first-line treatment of metastatic breast cancer. In: Annals of Oncology. 2004 ; Vol. 15, No. 3. pp. 440-449.

@article{98fb19fa2a7b41bcb169591c60ed1423,

title = "Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX{\texttrademark}/Doxil{\textregistered}) versus conventional doxorubicin for first-line treatment of metastatic breast cancer",

abstract = "Background: This study was designed to demonstrate that efficacy [progression-free survival (PFS)] of CAELYX{\texttrademark} [pegylated liposomal doxorubicin HCl (PLD)] is non-inferior to doxorubicin with significantly less cardiotoxicity in first-line treatment of women with metastatic breast cancer (MBC). Patients and methods: Women (n = 509) with MBC and normal cardiac function were randomized to receive either PLD 50 mg/m2 (every 4 weeks) or doxorubicin 60 mg/m2 (every 3 weeks). Cardiac event rates were based on reductions in left ventricular ejection fraction as a function of cumulative anthracycline dose. Results: PLD and doxorubicin were comparable with respect to PFS [6.9 versus 7.8 months, respectively; hazard ratio (HR) = 1.00; 95% confidence interval (CI) 0.82-1.22]. Subgroup results were consistent. Overall risk of cardiotoxicity was significantly higher with doxorubicin than PLD (HR = 3.16; 95%CI 1.58-6.31; P ",

keywords = "Cardiotoxicity, Pegylated liposomal doxorubicin",

author = "O'Brien, {Mary E R} and N. Wigler and M. Inbar and R. Rosso and E. Grischke and A. Santoro and R. Catane and Kieback, {D. G.} and P. Tomczak and Ackland, {S. P.} and F. Orlandi and L. Mellars and L. Alland and C. Tendler",

year = "2004",

month = mar,

doi = "10.1093/annonc/mdh097",

language = "English",

volume = "15",

pages = "440--449",

journal = "Annals of Oncology",

issn = "0923-7534",

publisher = "NLM (Medline)",

number = "3",

}

TY - JOUR

T1 - Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX™/Doxil®) versus conventional doxorubicin for first-line treatment of metastatic breast cancer

AU - O'Brien, Mary E R

AU - Wigler, N.

AU - Inbar, M.

AU - Rosso, R.

AU - Grischke, E.

AU - Santoro, A.

AU - Catane, R.

AU - Kieback, D. G.

AU - Tomczak, P.

AU - Ackland, S. P.

AU - Orlandi, F.

AU - Mellars, L.

AU - Alland, L.

AU - Tendler, C.

PY - 2004/3

Y1 - 2004/3

N2 - Background: This study was designed to demonstrate that efficacy [progression-free survival (PFS)] of CAELYX™ [pegylated liposomal doxorubicin HCl (PLD)] is non-inferior to doxorubicin with significantly less cardiotoxicity in first-line treatment of women with metastatic breast cancer (MBC). Patients and methods: Women (n = 509) with MBC and normal cardiac function were randomized to receive either PLD 50 mg/m2 (every 4 weeks) or doxorubicin 60 mg/m2 (every 3 weeks). Cardiac event rates were based on reductions in left ventricular ejection fraction as a function of cumulative anthracycline dose. Results: PLD and doxorubicin were comparable with respect to PFS [6.9 versus 7.8 months, respectively; hazard ratio (HR) = 1.00; 95% confidence interval (CI) 0.82-1.22]. Subgroup results were consistent. Overall risk of cardiotoxicity was significantly higher with doxorubicin than PLD (HR = 3.16; 95%CI 1.58-6.31; P

AB - Background: This study was designed to demonstrate that efficacy [progression-free survival (PFS)] of CAELYX™ [pegylated liposomal doxorubicin HCl (PLD)] is non-inferior to doxorubicin with significantly less cardiotoxicity in first-line treatment of women with metastatic breast cancer (MBC). Patients and methods: Women (n = 509) with MBC and normal cardiac function were randomized to receive either PLD 50 mg/m2 (every 4 weeks) or doxorubicin 60 mg/m2 (every 3 weeks). Cardiac event rates were based on reductions in left ventricular ejection fraction as a function of cumulative anthracycline dose. Results: PLD and doxorubicin were comparable with respect to PFS [6.9 versus 7.8 months, respectively; hazard ratio (HR) = 1.00; 95% confidence interval (CI) 0.82-1.22]. Subgroup results were consistent. Overall risk of cardiotoxicity was significantly higher with doxorubicin than PLD (HR = 3.16; 95%CI 1.58-6.31; P

KW - Cardiotoxicity

KW - Pegylated liposomal doxorubicin

UR - http://www.scopus.com/inward/record.url?scp=11144357506&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=11144357506&partnerID=8YFLogxK

U2 - 10.1093/annonc/mdh097

DO - 10.1093/annonc/mdh097

M3 - Article

C2 - 14998846

AN - SCOPUS:11144357506

VL - 15

SP - 440

EP - 449

JO - Annals of Oncology

JF - Annals of Oncology

SN - 0923-7534

IS - 3

ER -